QT Vascular’s 2Q2017 Revenue Increases 47.8% TO USD3.5 Million

SINGAPORE, 8 August 2017 – QT Vascular Ltd. (the “Company” or “QT Vascular”, and together with its subsidiaries, the “Group”), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that it achieved revenue growth of 47.8% to US$3.5 million for the three months ended 30 June 2017 (“2Q2017”).

QT Vascular’s 2Q2017 Revenue Increases 47.8% TO USD3.5 Million Read More »

DocuSign Named One of World’s Top 10 Best Private Cloud Companies by Forbes

NEW YORK (July 11, 2017) – Forbes today released the 2017 Cloud 100, the definitive ranking of the top 100 private cloud companies in the world, produced in collaboration with Bessemer Venture Partners and Salesforce Ventures. The second annual list profiles top-tier private companies leading the cloud technology revolution.

DocuSign Named One of World’s Top 10 Best Private Cloud Companies by Forbes Read More »

Savioke Joins Walt Disney’s Accelerator to Build the Future of Media and Entertainment

BURBANK, Calif., July 11, 2017 /PRNewswire/ — The Walt Disney Company today announced the eleven 2017 Disney Accelerator companies that are helping build the future of media and entertainment. The Disney Accelerator is designed to connect these Disney portfolio companies with the creativity, imagination, and expertise of The Walt Disney Company, providing them unprecedented access to Disney’s leadership team, mentorship, and support.

Savioke Joins Walt Disney’s Accelerator to Build the Future of Media and Entertainment Read More »

MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents

Singapore, 28 June 2017 – MerLion Pharmaceuticals (“MerLion”) today announced that a joint project with the Defence Science and Technology Laboratory, UK (Dstl) titled “‘Efficacy of Finafloxacin against Biological Threat Agents” has been awarded a grant from the United States’ Defense Threat Reduction Agency (DTRA) Chemical and Biological Defense Program.

MerLion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin against Biological Threat Agents Read More »

EDBI supports CXA’s partnership with Philips and Fortune 500 companies towards piloting an integrated digital workplace health solution

Singapore-headquartered health technology startup CXA Group (http://www.cxagroup.com/) has partnered with Philips and a select group of Fortune 500 companies to pilot an integrated workplace health solution, with the support of Singapore-based EDBI.

EDBI supports CXA’s partnership with Philips and Fortune 500 companies towards piloting an integrated digital workplace health solution Read More »

Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial

– With the Stanford Cancer Institute joining as a clinical trial partner, Tessa’s Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S.

Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial Read More »